Granata Bio
Industry
- Biotechnology
- Pharmaceuticals
- Specialty Pharmaceuticals
- Generic Drugs
See more in Biomedtracker
Latest on Granata Bio
In Vivo
• By Amanda Micklus
A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of
Scrip
• By Amanda Micklus
One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up
Scrip
• By Mandy Jackson
Venture capital fundraising data show that $100m-plus mega-rounds continue to account for the vast majority of biopharmaceutical company VC financings, with overall investment in large rounds and indi